The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

NCT ID: NCT04233346

Last Updated: 2025-04-04

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 93 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-09
• Study Completion Date: 2025-12-31

Brief Summary

This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

Detailed Description

The purpose of this study is to determine the safety and efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation.

Conditions

Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ponatinib 30mg

50% CML patients will be treated with 30mg/day ponatinib，the treatment will up to 60 months

Group Type: EXPERIMENTAL

Ponatinib 30mg OD

Intervention Type: DRUG

Ponatinib 30mg OD

Ponatinib 45mg

50% CP-CML patients will be randomized 45 mg dose group . Other patients (with AP-CML, BP-CML, Ph+ ALL) will only be assigned to 45 mg dose group(30 patients). The treatment will up to 60 months.

Group Type: EXPERIMENTAL

Ponatinib 45mg OD

Intervention Type: DRUG

Ponatinib 45mg OD

Interventions

Ponatinib 30mg OD

Ponatinib 30mg OD

Intervention Type: DRUG

Ponatinib 45mg OD

Ponatinib 45mg OD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

For CP-CML patients：

1. Patients with CP-CML

Patients must either meet criterion 2 or 3:

2. Be previously treated with and resistant or intolerant to either Dasatinib or Nilotinib:

3. Develop the T315I mutation after any TKI therapy;

4. Must be ≥18 years old.

5. Provide written informed consent.

6. Eastern Cooperative Oncology Group performance status ≤ 2.

7. Minimum life expectancy of 3 months or more.

8. Adequate renal function

9. Adequate hepatic function

10. Normal pancreatic status

11. Normal QTc interval on screening electrocardiogram (ECG) evaluation under resting state, defined as QTc of ≤ 450 ms in males or ≤ 470 ms in females.

For AP/BP-CML and ALL patients：

1. Patients with AP-CML and BP-CML or Ph+ ALL

2. Other inclusions are the same with No.2-No.11 of CP-CML patients

Exclusion Criteria

For CP-CML patients：

1. Received TKI therapy within 7 days prior to receiving the first dose of Ponatinib, or have not recovered (> grade 2 by NCI CTCAE v5.0) from AEs (except alopecia) due to agents previously administered.

2. Received other therapies (excluding hydroxyurea) as follows:

Received interferon, cytarabine, or immunotherapy within 14 days, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of Ponatinib.

3. Underwent autologous or allogeneic stem cell transplant < 60 days prior to receiving the first dose of Ponatinib;

4. Take medications that are known to be associated with Torsades de Pointes or QT interval prolongation.

5. Require concurrent treatment with immunosuppressive agents, other than corticosteroids prescribed for a short course of therapy.

6. Have previously been treated with Ponatinib or its analogues (including drug substance).

7. Patients with CP-CML are excluded if they are in CCyR.

8. Have active central nervous system (CNS) disease, as evidenced by cytology or pathology.

9. Have significant, uncontrolled, or active heart/brain/peripheral vascular diseases

10. Have a significant bleeding disorder unrelated to CML

11. Have a history of pancreatitis or alcohol abuse

12. Severely increased hypertriglyceridemia (triglycerides ≥ 5.6 mmol/L).

13. Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of orally administered Ponatinib.

14. Have been diagnosed with another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cervical cancer in situ, or controlled prostate cancer, which are allowed within 3 years).

15. Are pregnant or lactating.

16. Underwent major surgery (with the exception of minor surgical procedures, such as catheter placement or BM biopsy) within 14 days prior to first dose of Ponatinib.

17. Infectious diseases test showed anti-HIV (+) or anti-HCV (+) or HbsAg (+) or TP (+).

18. Suffer from any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the study drug.

19. Have hypertension (diastolic blood pressure ≥ 90 mmHg and/or systolic blood pressure ≥ 140 mm Hg).

20. Taken herbal preparations or related over-the-counter preparations containing Chinese herbal ingredients within 2 weeks prior to the first dose of Ponatinib.

21. Any subject who is not suitable for the study in the opinion of the investigator.

For AP/BP-CML and ALL patients：

1. Received TKI therapy within 7 days prior to receiving the first dose of Ponatinib, or have not recovered (> grade 2 by NCI CTCAE v.5.0) from AEs (except alopecia) due to agents previously administered.

2. Received other therapies (excluding hydroxyurea) as follows:

For AP-CML patients, received interferon, cytarabine, or immunotherapy within 14 days, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of Ponatinib.

For BP-CML patients, received chemotherapy within 7 days prior to the first dose of Ponatinib. Otherwise, 2a applies.

For Ph+ ALL patients, received corticosteroids within 24 hours before the first dose of Ponatinib; otherwise, 2a applies.

3. Underwent autologous or allogeneic stem cell transplant < 60 days prior to receiving the first dose of Ponatinib.

4. Take medications that are known to be associated with Torsades de Pointes or QT interval prolongation.

5. Require concurrent treatment with immunosuppressive agents, other than corticosteroids prescribed for a short course of therapy.

6. Have previously been treated with Ponatinib or its analogues (including drug substance).

7. Patients with AP-CML, BP-CML, or Ph+ ALL are excluded if they are in MaHR.

8. Patients with AP-CML, BP-CML, or Ph+ ALL are excluded if a baseline BM aspirate adequate for cell count and differential report is not available.

9. Have active central nervous system (CNS) disease as evidenced by cytology or pathology for AP-CML, BP-CML, or Ph+ ALL.

10. Have significant, uncontrolled, or active cardiovascular disease.

11. Have a significant bleeding disorder unrelated to CML or Ph+ ALL.

12. Other exclusions are the same with No.11-No.21 of CP-CML.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Otsuka Beijing Research Institute

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Juma Paty, Director

Role: STUDY_DIRECTOR

OBRI

Locations

Anhui Provincial Hospital

Hefei, Anhui, China

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Xiangya Hospital Central South University

Changsha, Hunan, China

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

Second hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Shenzhen Second People's Hospital

Shenzhen, Shenzhen, China

West China Hospital, Sichuan University

Chengdu, Sichuan, China

The First Affiliated Hospital of Medical School of Zhejiang University

Hangzhou, Zhejiang, China

1st affiliated hospital, Peking University

Beijing, , China

Hematology Hospital, Chinese Academy of Medical Sciences

Tianjin, , China

Countries

China

Other Identifiers

297-403-00003

Identifier Type: -

Identifier Source: org_study_id